Prosecution Insights
Prosecution Insights
13 pending office actions • 9 clients • 11 examiners • 11 art units • 0 of 13 (0%) have an AI response strategy ready • 26 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 13 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 13 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (15%) |
| §102 only | 2 (15%) |
| §112 only | 3 (23%) |
| No statute on record | 6 (46%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRISTOL, LYNN ANNE | 3 | 63.7% | +39.7% |
| MOU, LIYUAN | 1 | 43.2% | +58.1% |
| SHOWALTER, ALEXANDER KEITH | 1 | 52.1% | +53.0% |
| BABSON, NICOLE PLOURDE | 1 | 46.5% | +32.0% |
| OUSPENSKI, ILIA I | 1 | 77.6% | +20.3% |
| YOUTCHOM PENDIE, EMMANUEL LED | 1 | 60.0% | +50.0% |
| DAVIS, RUTH A | 1 | 60.6% | +31.1% |
| KOLKER, DANIEL E | 1 | 49.8% | +64.1% |
| ANDERSON, REBECCA L | 1 | 73.2% | +24.0% |
| RICCI, CRAIG D | 1 | 53.5% | +52.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17812800 | Methods for the Manufacture of Proteolytically Processed Polypeptides | KOLKER, DANIEL E | 149d overdue |
| 18258914 | HOMOGENEOUS BIOPOLYMER SUSPENSIONS, PROCESSES FOR MAKING SAME AND USES THEREOF | BABSON, NICOLE PLOURDE | 79d overdue |
| 18061791 | ANTI-CD277 ANTIBODIES AND USES THEREOF | OUSPENSKI, ILIA I | 1d overdue |
| 18052131 | IMMUNOSILENCING Fc VARIANTS | YOUTCHOM PENDIE, EMMANUEL LED | 7d |
| 19086136 | FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | MOU, LIYUAN | 9d |
| 17776533 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | RICCI, CRAIG D | 9d |
| 18506625 | MACROCYCLIC COMPOUNDS AND USES THEREOF | SHOWALTER, ALEXANDER KEITH | 12d |
| 17786708 | POLYPEPTIDES, PROTEIN COMPLEXES AND METHOD FOR MAKING SAME | BRISTOL, LYNN ANNE | 20d |
| Client (Assignee) | Pending OAs |
|---|---|
| Ipsen | 3 |
| Viridian Therapeutics, Inc. | 2 |
| Praeventix, LLC | 2 |
| Hangzhou Polymed Biopharmaceuticals | 1 |
| Theseus Pharmaceuticals, Inc. | 1 |
| 11584022 CANADA INC. | 1 |
| KISOJI BIOTECHNOLOGY INC. | 1 |
| Nantes Université | 1 |
| VISTERRA, INC. | 1 |
| Art Unit | Apps |
|---|---|
| 1643 | 3 |
| 1628 | 1 |
| 1629 | 1 |
| 1619 | 1 |
| 1644 | 1 |
| 1647 | 1 |
| 1699 | 1 |
| 1645 | 1 |
| 1626 | 1 |
| 1611 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19242715 | COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE | Viridian Therapeutics, Inc. | BRISTOL, LYNN ANNE | 1643 | Other | Non-Final OA | 34d | Pending | Jun 18, 2025 |
| 19086136 | FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | Hangzhou Polymed Biopharmaceuticals, Inc. | MOU, LIYUAN | 1628 | Other | Final Rejection | 9d | Pending | Mar 21, 2025 |
| 18506625 | MACROCYCLIC COMPOUNDS AND USES THEREOF | Theseus Pharmaceuticals, Inc. | SHOWALTER, ALEXANDER KEITH | 1629 | §112 | Non-Final OA | 12d | Pending | Nov 10, 2023 |
| 18364620 | COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE | Viridian Therapeutics, Inc. | BRISTOL, LYNN ANNE | 1643 | Other | Non-Final OA | 39d | Pending | Aug 03, 2023 |
| 18258914 | HOMOGENEOUS BIOPOLYMER SUSPENSIONS, PROCESSES FOR MAKING SAME AND USES THEREOF | 11584022 Canada Inc. | BABSON, NICOLE PLOURDE | 1619 | §102 | Non-Final OA | 79d overdue | Pending | Jun 22, 2023 |
| 17786708 | POLYPEPTIDES, PROTEIN COMPLEXES AND METHOD FOR MAKING SAME | Kisoji Biotechnology Inc. | BRISTOL, LYNN ANNE | 1643 | Other | Non-Final OA | 20d | Pending | Dec 20, 2022 |
| 18061791 | ANTI-CD277 ANTIBODIES AND USES THEREOF | Nantes Université | OUSPENSKI, ILIA I | 1644 | §112 | Non-Final OA | 1d overdue | Pending | Dec 05, 2022 |
| 18052131 | IMMUNOSILENCING Fc VARIANTS | VISTERRA, INC. | YOUTCHOM PENDIE, EMMANUEL LED | 1647 | §103 | Final Rejection | 7d | Pending | Nov 02, 2022 |
| 17759674 | TREATMENT OF SKIN CONDITIONS | Ipsen Biopharm Limited | DAVIS, RUTH A | 1699 | §103 | Final Rejection | 40d | Pending | Jul 28, 2022 |
| 17812800 | Methods for the Manufacture of Proteolytically Processed Polypeptides | Ipsen Biopharm Limited | KOLKER, DANIEL E | 1645 | Other | Non-Final OA | 149d overdue | Pending | Jul 15, 2022 |
| 17776531 | NOVEL FUNCTIONALIZED LACTONES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Praeventix, LLC | ANDERSON, REBECCA L | 1626 | §112 | Final Rejection | 28d | Pending | May 12, 2022 |
| 17776533 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Praeventix, LLC | RICCI, CRAIG D | 1611 | Other | Final Rejection | 9d | Pending | May 12, 2022 |
| 17754216 | TREATMENT OF NEUROLOGICAL DISORDERS | Ipsen Biopharm Limited | CHOWDHURY, IQBAL HOSSAIN | 1656 | §102 | Non-Final OA | 22d | Pending | Mar 28, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial